Literature DB >> 16247081

RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma.

Mukesh K Sharma1, Barbara A Zehnbauer, Mark A Watson, David H Gutmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16247081     DOI： 10.1212/01.wnl.0000180409.78098.d7

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  33 in total

Review 1.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

Authors:  Eric H Raabe; Kah Suan Lim; Julia M Kim; Alan Meeker; Xing-Gang Mao; Guido Nikkhah; Jarek Maciaczyk; Ulf Kahlert; Deepali Jain; Eli Bar; Kenneth J Cohen; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

3.  Oncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosis.

Authors:  Myung-Jeom Ryu; Yangang Liu; Xiaofen Zhong; Juan Du; Nicholas Peterson; Guangyao Kong; Hongda Li; Jinyong Wang; Shahriar Salamat; Qiang Chang; Jing Zhang
Journal:  J Biol Chem       Date:  2012-05-10       Impact factor: 5.157

Review 4.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

6.  Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT).

Authors:  Marco Gessi; Sally R Lambert; Libero Lauriola; Andreas Waha; V Peter Collins; Torsten Pietsch
Journal:  J Neurooncol       Date:  2012-07-20       Impact factor: 4.130

7.  Trametinib for progressive pediatric low-grade gliomas.

Authors:  Maria Kondyli; Valérie Larouche; Christine Saint-Martin; Benjamin Ellezam; Lauranne Pouliot; Daniel Sinnett; Geneviève Legault; Louis Crevier; Alex Weil; Jean-Pierre Farmer; Nada Jabado; Sébastien Perreault
Journal:  J Neurooncol       Date:  2018-08-10       Impact factor: 4.130

Review 8.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

Review 9.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 10.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.